In clinical trials, tirzepatide demonstrated reductions in hemoglobin A1c of up to 2.5% and weight loss of approximately 15-21% of body weight at higher doses after 72 weeks of treatment, with results varying by dose and patient population
Length and risks of surgery are decreased, but some patients have persistent pain or other problems with the remaining bladder
Incredible staff, Nicole was great and easy to communicate with
There is no direct interaction, though there is one overlap worth managing
Populations at elevated risk are people on blood thinners, immune suppression, and those with severe kidney or liver disease
That way, if accessing medication becomes a problem, they wouldve at least had 6 months of coaching to strive for their goal weight with and without medication and then maintain it with newly developed behavioral changes learned in the 6-month program